Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fractional vs Standard Booster Doses of COVID-19 Vaccines in Indonesia
NCT05387317Phase 3Withdrawn
- Sponsor
- Murdoch Children's Research Institute
- Start
- Apr 2024
- Primary completion
- Jan 2025
- Modality
- Viral Vector Vaccines, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of tozinameran, ChAdOx1 nCoV-19 and elasomeran in coronavirus disease 2019 (COVID-19) (12 arms), sponsored by Murdoch Children's Research Institute. Primary endpoints: SARS-CoV-2 specific Immunoglobulin (Ig)G antibodies at 28 days and Incidence of solicited systemic and local reactions (reactogenicity) at 7 days. Planned start Apr 2024; status: withdrawn.
02
Drugs
tozinameranChAdOx1 nCoV-19elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05387317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05387317.